MedTech Acquisition Corp. to merge with TriSalus Life Sciences for $220M in stock

TriSalus Life Sciences, Inc.

Merger consideration: $220M paid entirely in MTAC common stock valued at $10.00 per share.
Closing conditions include MTAC having at least $60M in available cash and net tangible assets ≥$5M.
Sponsor agrees to forfeit 2,187,500 shares and subject 3,125,000 shares to vesting restrictions.
Non-binding term sheet for up to $50M of 8.0% senior secured convertible notes from Magnetar Capital.
TriSalus stockholders subject to 365-day lock-up; lock-up ends earlier if stock hits $12 for 20 of 30 days after 150 days.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation and MTAC Merger Sub, Inc. valued at $220,000,000 (effective 2022-11-11).

Action: entry
Agreement: merger
Counterparty: MedTech Acquisition Corporation and MTAC Merger Sub, Inc.
Value: $220,000,000
Effective: 2022-11-11

Exact text from the filing

On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (" MTAC "), entered into an Agreement and Plan of Merger (the " Merger Agreement ") with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (" Merger Sub "), and TriSalus Life Sciences, Inc., a Delaware corporation (" TriSalus ")

View on SEC.gov

277 material agreements filed in the last 30 days. Browse all material agreements →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117666

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.